Literature DB >> 11708830

Leishmania donovani: evolution and architecture of the splenic cellular immune response related to control of infection.

P C Melby1, A Tabares, B I Restrepo, A E Cardona, H S McGuff, J M Teale.   

Abstract

Infection with the protozoan Leishmania donovani in humans is usually subclinical. Parasites probably persist for the life of the host and the low-level infection is controlled by the cellular immune response. To better understand the mechanisms related to the control of infection, we studied the evolution and architecture of the splenic cellular immune response in a murine model that is most representative of human subclinical infection. Following systemic inoculation with L. donovani, the parasites were primarily localized to the macrophage-rich splenic red pulp. There was an initial increase in the numbers of T cells and dendritic cells in the periarteriolar lymphoid sheath and marginal zone, but the red pulp (where parasitized macrophages were prominent) remained free of these cells until later in the course of infection. Thus, T cells did not colocalize with parasitized red pulp macrophages until later in the course of infection. Early in the course of infection, IL-10 production within the marginal zone and TGF-beta production by cells in the red pulp were prominent. These macrophage-inhibitory cytokines may contribute to the establishment of the infection and early parasite replication. By day 28 of infection, when the visceral parasite burden began to decline, the number of IL-10-producing spleen cells was back to the baseline level, but IFN-gamma production was higher and the number of IL-12-producing cells was increased dramatically. At this time T cells and dendritic cells had moved out of the lymphoid follicle and marginal zone into the red pulp where the parasites were located. These findings therefore suggest that control of infection is associated with IFN-gamma and IL-12 production and migration of T cells and dendritic cells to the site of chronic parasitism. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11708830     DOI: 10.1006/expr.2001.4640

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  20 in total

1.  Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.

Authors:  Henry W Murray; Kathleen C Flanders; Debra D Donaldson; Joseph P Sypek; Philip J Gotwals; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

2.  UDP-Gal: N-acetylglucosamine beta 1-4 galactosyltransferase expressing live attenuated parasites as vaccine for visceral leishmaniasis.

Authors:  Siddhartha Kumar Bhaumik; Manoj Kumar Singh; Subir Karmakar; Tripti De
Journal:  Glycoconj J       Date:  2008-11-13       Impact factor: 2.916

3.  Endogenous interleukin-18 is involved in immunity to Leishmania donovani but its absence does not adversely influence the therapeutic activity of sodium stibogluconate.

Authors:  Alexander B Mullen; Catherine E Lawrence; Emma McFarlane; Xiao-Quing Wei; Katharine C Carter
Journal:  Immunology       Date:  2006-07-26       Impact factor: 7.397

4.  Evaluation of parasitological and immunological parameters of Leishmania chagasi infection in BALB/c mice using different doses and routes of inoculation of parasites.

Authors:  Dulcilene M Oliveira; Mariana Amália F Costa; Miguel A Chavez-Fumagalli; Diogo G Valadares; Mariana C Duarte; Lourena E Costa; Vivian T Martins; Rosângela F Gomes; Maria N Melo; Manuel Soto; Carlos Alberto P Tavares; Eduardo Antonio F Coelho
Journal:  Parasitol Res       Date:  2011-09-14       Impact factor: 2.289

Review 5.  Role of chemokines in regulation of immunity against leishmaniasis.

Authors:  Steve Oghumu; Claudio M Lezama-Dávila; Angelica P Isaac-Márquez; Abhay R Satoskar
Journal:  Exp Parasitol       Date:  2010-03-03       Impact factor: 2.011

6.  Immunoprotective responses of T helper type 1 stimulatory protein-S-adenosyl-L-homocysteine hydrolase against experimental visceral leishmaniasis.

Authors:  P Khare; A K Jaiswal; C D P Tripathi; S Sundar; A Dube
Journal:  Clin Exp Immunol       Date:  2016-04-27       Impact factor: 4.330

7.  Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis.

Authors:  Henry W Murray; Elaine B Brooks; Jennifer L DeVecchio; Frederick P Heinzel
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

8.  Loss of dendritic cell migration and impaired resistance to Leishmania donovani infection in mice deficient in CCL19 and CCL21.

Authors:  Manabu Ato; Asher Maroof; Soombul Zubairi; Hideki Nakano; Terutaka Kakiuchi; Paul M Kaye
Journal:  J Immunol       Date:  2006-05-01       Impact factor: 5.422

Review 9.  Mechanisms of resistance and susceptibility to experimental visceral leishmaniosis: BALB/c mouse versus Syrian hamster model.

Authors:  Ana Nieto; Gustavo Domínguez-Bernal; José A Orden; Ricardo De La Fuente; Nadia Madrid-Elena; Javier Carrión
Journal:  Vet Res       Date:  2011-02-23       Impact factor: 3.683

10.  Leishmania donovani infection induces anemia in hamsters by differentially altering erythropoiesis in bone marrow and spleen.

Authors:  William P Lafuse; Ryan Story; Jocelyn Mahylis; Gaurav Gupta; Sanjay Varikuti; Heidi Steinkamp; Steve Oghumu; Abhay R Satoskar
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.